Compare Regeneron Pharmaceuticals Inc (REGN) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $58.89. The key difference: Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Vanguard Emerging Markets Stock Index Fund ETF pays none, and Vanguard Emerging Markets Stock Index Fund ETF is trading nearer its 52-week high, Regeneron Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| REGN | VWO | |
|---|---|---|
Market Cap | $70.79B | — |
Sector | Health | — |
52-Week High | $812.27 | $61.24 |
52-Week Low | $545.46 | $49.54 |
Enterprise Value | $64.74B | — |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
VWO trades at $57.93, up 0.16% today, with a bearish technical signal from moving averages and oscillators showing neutral readings. The ETF's low expense ratio of 0.06% and a 2.4% dividend yield are key attractions, though financial ratios are unavailable. Recent news highlights emerging markets' record inflows and comparisons with competing funds, emphasizing cost advantages and exposure to developing economies.
Outlook is mixed: strong institutional interest and low costs support long-term growth in emerging markets, but bearish technicals and geopolitical risks in regions like China pose headwinds. Investors should weigh the ETF's diversification benefits against volatility from economic uncertainties and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
